Oh, Seung-June
Cho, Sung Tae
Kuo, Hann-Chorng
Chou, Eric Chieh-Lung
Hsu, Yu-Chao
Lee, Kyu-Sung http://orcid.org/0000-0003-0891-2488
Hadi, Farid
Song, Yi
Sumarsono, Budiwan
Clinical trials referenced in this document:
Documents that mention this clinical trial
Treatment Patterns with Mirabegron and Antimuscarinics for Overactive Bladder: A Prospective, Registry Study in Taiwan and South Korea (FAITH)
https://doi.org/10.1007/s12325-024-02784-2
Funding for this research was provided by:
Astellas Pharma
Article History
Received: 17 August 2023
Accepted: 11 January 2024
First Online: 2 March 2024
Declarations
:
: Seung-June Oh has received grant support from Astellas and was a moderator of the “Astellas Asia-Oceania closed symposium” held on February 15, 2019, in Seoul, South Korea. Sung Tae Cho, Hann-Chorng Kuo, Eric Chieh-Lung Chou, Yu-Chao Hsu, and Kyu-Sung Lee have nothing to disclose outside of the submitted work. Farid Hadi is an employee of Astellas Pharma, Inc. Yi Song and Budiwan Sumarsono were employees at Astellas Pharma, Inc. at the time of the study.
: The protocol was approved by the institutional review board or independent ethics committee at each site (Supplemental Table InternalRef removed) and the study was conducted in accordance with the Declaration of Helsinki. Patients provided written informed consent.